CABB Group has entered into a definitive agreement to sell its US-based subsidiary, Jayhawk Fine Chemicals, to India’s Anupam Rasayan in a transaction valued at approximately $150 million. The deal marks a strategic inflection point for both companies—accelerating CABB’s portfolio pivot toward higher-margin pharmaceutical and life science specialties, while giving Anupam Rasayan its first onshore manufacturing footprint in the United States.

For CABB, the divestment of Jayhawk represents a deliberate rebalancing of its asset base. The group has been steadily repositioning itself away from industrial, electronics, and semiconductor-linked chemistries toward pharma and life science specialties, where regulatory complexity, process know-how, and long-term customer contracts offer structurally superior margins. Post-transaction, CABB’s growth strategy will be increasingly centered on its European production sites, which form the backbone of its specialty pharma platform.

Jayhawk Fine Chemicals, located in the US, has long been a technically sophisticated asset with capabilities in complex, high-value chemistries. Previously owned by Evonik before being acquired by Permira in 2018 and subsequently integrated into CABB, the site has served customers across performance materials, electronics, and other advanced industrial applications. Its sale underscores CABB’s view that future value creation lies less in capital-intensive industrial applications and more in regulated, innovation-driven life science markets.

For Anupam Rasayan, the acquisition is transformational. The deal marks the company’s entry into onshore US manufacturing at a time when global customers are reassessing supply-chain resilience, geographic diversification, and proximity to end markets. Jayhawk’s US operations position Anupam closer to strategic customers in developed markets and enable it to move further up the value chain by manufacturing critical N-1 and advanced intermediate molecules used in electronics, semiconductors, aerospace, and performance materials.

Strategically, the transaction accelerates Anupam Rasayan’s evolution from an India-centric custom synthesis player into a more globally integrated specialty chemicals manufacturer. While the company’s existing six manufacturing facilities in Gujarat underpin its strength in cost-efficient, complex chemistry execution, the addition of a US asset adds customer intimacy, faster response times, and greater credibility in regulated and high-performance end markets.

The acquisition also reflects a broader industry trend: Indian specialty chemical companies are no longer limiting global ambitions to exports alone, but are increasingly pursuing overseas manufacturing assets to de-risk geopolitics, align with customer localization strategies, and capture higher-value segments of the specialty chemicals value chain.

Once completed, the transaction will see Jayhawk change ownership for the third time in less than a decade, but with a notably different strategic role. Under Anupam Rasayan, the US facility is expected to serve as a growth platform rather than a non-core asset—integrated into a global operating model that combines India-based chemistry scale with onshore manufacturing in key developed markets.

The deal reinforces a clear strategic symmetry: CABB sharpens its focus on life sciences-led specialty growth, while Anupam Rasayan takes a decisive step toward becoming a globally embedded specialty chemicals player with assets and customers on both sides of the Atlantic.